Dysregulation of EGFR pathway in EphA2 cell subpopulation significantly associates with poor prognosis in colorectal cancer

作者: Mariangela De Robertis , Luisa Loiacono , Caterina Fusilli , Maria Luana Poeta , Tommaso Mazza

DOI: 10.1158/1078-0432.CCR-16-0709

关键词:

摘要: Purpose: EphA2 receptor is involved in multiple cross-talks with other cellular networks including EGFR, FAK and VEGF pathways, which it collaborates to stimulate cell migration, invasion metastasis. Colorectal cancer (CRC) overexpression has also been correlated stem-like properties of cells tumor malignancy. We investigated the molecular crosstalk microRNAs modulation EGFR pathways. We explored role EphA2/EGFR pathway mediators as prognostic factors or predictors cetuximab benefit CRC patients. Experimental Design: Gene expression analysis was performed EphA2high isolated from AOM/DSS murine model by FACS-assisted procedures. Six independent cohorts patients were stratified determine potential a signature its effect on treatment response. Results: identified gene pattern (EphA2, Efna1, Ptpn12, Atf2) reflecting activation pathways coherent dysregulation mir-26b mir-200a. Such showed significance stage I-III patients, both univariate multivariate analysis. In IV WT KRAS, EphA2/Efna1/EGFR status significantly associated poor response treatment. Furthermore, combined relative resistance, independently KRAS mutation status. Conclusions: These results suggest that genes, linked possible control mir-200a mir-26b, could be proposed novel biomarkers. Moreover, mechanism resistance alternative mutations.

参考文章(52)
Michael S. Kinch, Kelly Carles-Kinch, Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer Clinical & Experimental Metastasis. ,vol. 20, pp. 59- 68 ,(2003) , 10.1023/A:1022546620495
Nicole Dodge Zantek, Michael S. Kinch, Daniel P. Zelinski, Jane C. Stewart, Armando R. Irizarry, EphA2 overexpression causes tumorigenesis of mammary epithelial cells Cancer Research. ,vol. 61, pp. 2301- 2306 ,(2001)
Jacques Ferlay, Isabelle Soerjomataram, Rajesh Dikshit, Sultan Eser, Colin Mathers, Marise Rebelo, Donald Maxwell Parkin, David Forman, Freddie Bray, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer. ,vol. 136, ,(2015) , 10.1002/IJC.29210
Mariangela De Robertis, Maddalena Arigoni, Luisa Loiacono, Federica Riccardo, Raffaele Adolfo Calogero, Yana Feodorova, Dessislava Tashkova, Vesselin Belovejdov, Victoria Sarafian, Federica Cavallo, Emanuela Signori, Novel insights into Notum and glypicans regulation in colorectal cancer Oncotarget. ,vol. 6, pp. 41237- 41257 ,(2015) , 10.18632/ONCOTARGET.5652
Giulia Siravegna, Benedetta Mussolin, Michela Buscarino, Giorgio Corti, Andrea Cassingena, Giovanni Crisafulli, Agostino Ponzetti, Chiara Cremolini, Alessio Amatu, Calogero Lauricella, Simona Lamba, Sebastijan Hobor, Antonio Avallone, Emanuele Valtorta, Giuseppe Rospo, Enzo Medico, Valentina Motta, Carlotta Antoniotti, Fabiana Tatangelo, Beatriz Bellosillo, Silvio Veronese, Alfredo Budillon, Clara Montagut, Patrizia Racca, Silvia Marsoni, Alfredo Falcone, Ryan B Corcoran, Federica Di Nicolantonio, Fotios Loupakis, Salvatore Siena, Andrea Sartore-Bianchi, Alberto Bardelli, Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients Nature Medicine. ,vol. 21, pp. 795- 801 ,(2015) , 10.1038/NM.3870
Malgorzata Gozdecka, Wolfgang Breitwieser, The roles of ATF2 (activating transcription factor 2) in tumorigenesis. Biochemical Society Transactions. ,vol. 40, pp. 230- 234 ,(2012) , 10.1042/BST20110630
Alexios Strimpakos, George Pentheroudakis, Vassiliki Kotoula, Wendy De Roock, George Kouvatseas, Pavlos Papakostas, Thomas Makatsoris, Demetris Papamichael, Anna Andreadou, Joseph Sgouros, Adamantia Zizi-Sermpetzoglou, Athina Kominea, Despina Televantou, Evangelia Razis, Eleni Galani, Dimitrios Pectasides, Sabine Tejpar, Konstantinos Syrigos, George Fountzilas, The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab. Clinical Colorectal Cancer. ,vol. 12, pp. 267- 274 ,(2013) , 10.1016/J.CLCC.2013.07.001
Stine Aske Danielsen, Peter Wold Eide, Arild Nesbakken, Tormod Guren, Edward Leithe, Ragnhild A. Lothe, Portrait of the PI3K/AKT pathway in colorectal cancer ☆ Biochimica et Biophysica Acta. ,vol. 1855, pp. 104- 121 ,(2015) , 10.1016/J.BBCAN.2014.09.008
Kim H.T. Paraiso, Meghna Das Thakur, Bin Fang, John M. Koomen, Inna V. Fedorenko, Jobin K. John, Hensin Tsao, Keith T. Flaherty, Vernon K. Sondak, Jane L. Messina, Elena B. Pasquale, Alejandro Villagra, Uma N. Rao, John M. Kirkwood, Friedegund Meier, Sarah Sloot, Geoffrey T. Gibney, Darrin Stuart, Hussein Tawbi, Keiran S.M. Smalley, Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapy–Mediated Metastatic Melanoma Phenotype Cancer Discovery. ,vol. 5, pp. 264- 273 ,(2015) , 10.1158/2159-8290.CD-14-0293
Dana M. Brantley-Sieders, Guanglei Zhuang, Donna Hicks, Wei Bin Fang, Yoonha Hwang, Justin M.M. Cates, Karen Coffman, Dowdy Jackson, Elizabeth Bruckheimer, Rebecca S. Muraoka-Cook, Jin Chen, The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. Journal of Clinical Investigation. ,vol. 118, pp. 64- 78 ,(2008) , 10.1172/JCI33154